PoTS research & news

This multicentre UK study enrolled 124 adults (mean age 32, 89% female) across six NHS sites. The primary outcome was reduction in standing heart rate at 10 minutes; secondary outcomes included COMPASS-31 autonomic symptom score, SF-36 quality of life, and treatment discontinuation rates.

At 12 months, both agents produced significant reductions in standing HR (ivabradine −18 bpm; propranolol −14 bpm, p=0.04 for superiority of ivabradine). Importantly, discontinuation due to side effects was substantially higher in the propranolol arm (28% vs 9%), driven predominantly by fatigue and exercise intolerance. COMPASS-31 scores improved in both groups, with no significant difference between agents.

Limitations: Open-label design beyond 4 weeks; predominantly young female cohort limits generalisability; propranolol dose may have been subtherapeutic in some participants.

The review follows sustained advocacy from patient groups including Dysautonomia UK and POTS UK, and builds on the 2025 Scottish Parliament motion recognising the diagnostic delays experienced by patients with autonomic dysfunction. The scope includes mapping of current referral routes across all fourteen health boards, identification of bottlenecks, and consultation with specialist clinicians and patient representatives.

The review will consider whether a dedicated regional autonomic clinic service — along the lines of those operating in London and Newcastle — would be feasible within the Scottish NHS. A consultation exercise open to patients and clinicians is expected to launch in June 2026.

This prospective cohort study followed 312 patients with confirmed post-COVID POTS (diagnosed via active stand test or tilt-table testing) from twelve UK sites, with assessments at 6, 12, 18, and 24 months. At two years, 41% of participants had achieved symptomatic remission (defined as COMPASS-31 score <20 and return to pre-illness functional level); 34% had significant ongoing disability; and 25% had partial improvement.

Predictors of poorer outcome included: older age at illness onset, more severe acute COVID-19, presence of coexisting ME/CFS features (particularly post-exertional malaise), and delayed diagnosis (>12 months from onset). Patients who began a structured exercise programme within 6 months had significantly better 24-month outcomes (OR 2.4, 95% CI 1.4–4.1).

Limitations: Predominantly hospital-referred cohort; likely underrepresents milder cases managed in primary care. Loss to follow-up at 24 months was 18%.

The surveillance review covered literature published since 2021 in orthostatic hypotension, orthostatic tachycardia, and vasovagal syncope. Reviewers noted significant growth in the evidence base for POTS, particularly regarding post-COVID POTS and pharmacological management, and recommended a formal scoping exercise to determine whether a dedicated NICE guideline for POTS would be warranted.

Currently, POTS is addressed only tangentially in NICE guidance on syncope (NG109). The absence of dedicated NICE guidance on POTS is frequently cited as a barrier to equitable, consistent care across the NHS. The scoping exercise is expected to begin in late 2026.

This is one of the largest studies to date examining the autoimmune hypothesis in POTS. Elevated beta-2 adrenergic receptor (β2-AR) antibody titres were found in 31% of POTS patients versus 4% of healthy controls (p<0.001). Anti-muscarinic M2 and M3 receptor antibodies were found in 18% and 22% respectively. Patients with elevated β2-AR antibodies were more likely to have the hyperadrenergic phenotype, higher standing noradrenaline levels, and a subacute post-viral onset.

This study does not establish causation, and the clinical utility of antibody testing in routine POTS management remains unclear — there is currently no validated treatment strategy targeting these antibodies, and testing is not widely available outside research centres.

Limitations: Cross-sectional design; tertiary referral centre cohort (likely enriched for complex cases); antibody assays are not standardised across laboratories.

The updated charter sets out what patients with POTS and related dysautonomias should be able to expect from their NHS care — including timely diagnosis, access to specialist referral, individualised management plans, and appropriate sick note support. The GP information pack is a concise, evidence-referenced two-page document designed to support primary care clinicians who may have limited familiarity with POTS.

Both documents are available to download freely from the Dysautonomia UK website. The GP pack is formatted for printing and can be shared during consultations or attached to GP referral letters.

Pooled analysis found a mean reduction in standing HR of 9.4 bpm (95% CI 6.2–12.6 bpm) with compression garments compared to no compression, with abdominal binders producing greater effect than knee- or thigh-high stockings alone (MD −13.1 vs −6.8 bpm). There was no significant effect on supine HR or supine blood pressure. Patient-reported symptom improvement was consistent but heterogeneous across trials.

Quality of evidence was rated moderate (GRADE), with the primary limitation being that blinding of participants is not possible in compression trials. The review found no significant difference in effect between 15–20 mmHg and 20–30 mmHg compression classes, though 20–30 mmHg is standard clinical recommendation.

The motion, supported by MSPs from five parties, cited evidence that the average diagnostic delay for POTS in Scotland exceeds four years, and highlighted the particular impact on working-age women who are most commonly affected. It called specifically for: recognition of POTS in NHS Scotland guidance documents; development of a clear primary care referral pathway; and consideration of a dedicated regional autonomic assessment service.

The motion did not pass as government business but received a formal government response acknowledging the concerns raised. This appears to have contributed to the announcement of the NHS Scotland dysautonomia referral pathway review (see March 2026 entry above).

All fifteen participants completed the 12-week protocol. Mean standing HR at 10 minutes fell from 118 to 94 bpm (p=0.001). COMPASS-31 scores improved by a mean of 18 points. Twelve of fifteen participants elected to continue beyond 12 weeks. No serious adverse events were recorded; minor infusion reactions occurred in two patients.

This is a small, open-label, uncontrolled study and cannot establish efficacy. The placebo effect of regular clinical contact and IV infusion is substantial. Nevertheless, the magnitude of response and feasibility data are encouraging enough to support a larger controlled trial, which the authors indicate is planned.